Sanghvi Y S, Larson S B, Matsumoto S S, Nord L D, Smee D F, Willis R C, Avery T L, Robins R K, Revankar G R
Nucleic Acid Research Institute, Costa Mesa, California 92626.
J Med Chem. 1989 Mar;32(3):629-37. doi: 10.1021/jm00123a022.
A novel and direct synthesis of the antiviral and antitumor agent 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (ARPP, 8) and its alpha-anomer (11) has been developed. Treatment of 2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine (1) with 2,3-O-isopropylidene-D-ribofuranosylamine gave an anomeric mixture of 2,4,6-trichloro-8-(2,3-O-isopropylidene-beta- and -alpha-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidines (3 and 4) in a ratio of 1.0:0.7. A nucleophilic displacement of the 4-chloro group of 3 and 4 with NH3 furnished 4-amino-2,6-dichloro-8-[(2,3-O-isopropylidene-beta-D-ribofuranosyl)amino ] pyrimido[5,4-d]pyrimidine (6) and its alpha-anomer (9), respectively. Catalytic hydrogenation of 6 and 9, followed by deisopropylidenation gave ARPP (8) and the alpha-anomer 11, respectively. Similarly, 3 and 4 have been transformed to 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido-[5,4-d]pyrimidine (MRPP, 14) and its alpha-anomer (17). Application of this procedure to 3 with NH2Me or NHMe2 resulted in the synthesis of 4-(methylamino)- and 4-(dimethylamino)-8-(beta-D-ribofuranosylamino)pyrimido [5,4-d]pyrimidine (24 and 27, respectively). A synthesis of 8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidin-4(3H)-one (21) has also been accomplished from 3 in three steps. Selective hydrogenation of 6 furnished 4-amino-6-chloro-8-[(2,3-O-isopropylidene-beta-D-ribofuranosyl)amino] pyrimido[5,4-d]pyrimidine (36), the structure of which was established by single-crystal X-ray diffraction analysis. Deisopropylidenation of 36 gave 6-chloro-ARPP (37). Extended treatment of 36 with NH3 furnished 4,6-diamino-8-[(2,3-O-isopropylidene-beta-D-ribofuranosyl)amino]pyrimido [5,4-d]pyrimidine (34), which on deisopropylidenation gave 6-amino-ARPP (35). An unambiguous synthesis of 34 and 36 has also been accomplished by the reaction of 4,6,8-trichloropyrimido[5,4-d]pyrimidine (28) with 2, followed by the treatment with NH3. Nucleophilic displacement studies with 1, 6, and 28 indicated the reactivity of the halogens in these compounds is in the order of 8 greater than 4 greater than 6 greater than 2. The structures of 3 and 9 have been assigned on the basis of 1H NMR data and further confirmed by single-crystal X-ray diffraction analysis. The exocyclic aminonucleosides synthesized during this study were tested for their activity against several RNA and DNA viruses in vitro and against L1210, WI-L2, and LoVo/L in cell culture. The effect of these compounds on the de novo nucleic acid biosynthesis has been studied. Compound 14 (MRPP) exhibited enhanced activity against L1210 in vivo, when compared to ARPP (8).
已开发出一种新颖且直接的方法来合成抗病毒和抗肿瘤药物4-氨基-8-(β-D-呋喃核糖基氨基)嘧啶并[5,4-d]嘧啶(ARPP, 8)及其α-异构体(11)。用2,3-O-异亚丙基-D-呋喃核糖胺处理2,4,6,8-四氯嘧啶并[5,4-d]嘧啶(1),得到2,4,6-三氯-8-(2,3-O-异亚丙基-β-和-α-D-呋喃核糖基氨基)嘧啶并[5,4-d]嘧啶(3和4)的异头物混合物,比例为1.0:0.7。用NH₃对3和4的4-氯基团进行亲核取代,分别得到4-氨基-2,6-二氯-8-[(2,3-O-异亚丙基-β-D-呋喃核糖基)氨基]嘧啶并[5,4-d]嘧啶(6)及其α-异构体(9)。6和9经催化氢化,然后脱异亚丙基化,分别得到ARPP(8)和α-异构体11。类似地,3和4已转化为4-甲氧基-8-(β-D-呋喃核糖基氨基)嘧啶并[5,4-d]嘧啶(MRPP, 14)及其α-异构体(17)。将此方法应用于3与NH₂Me或NHMe₂的反应,得到4-(甲氨基)-和4-(二甲氨基)-8-(β-D-呋喃核糖基氨基)嘧啶并[5,4-d]嘧啶(分别为24和27)。还通过三步反应从3完成了8-(β-D-呋喃核糖基氨基)嘧啶并[5,4-d]嘧啶-4(3H)-酮(21)的合成。6的选择性氢化得到4-氨基-6-氯-8-[(2,3-O-异亚丙基-β-D-呋喃核糖基)氨基]嘧啶并[5,4-d]嘧啶(36),其结构通过单晶X射线衍射分析确定。36的脱异亚丙基化得到6-氯-ARPP(37)。用NH₃对36进行长时间处理得到4,6-二氨基-8-[(2,3-O-异亚丙基-β-D-呋喃核糖基)氨基]嘧啶并[5,4-d]嘧啶(34),其脱异亚丙基化后得到6-氨基-ARPP(35)。通过4,6,8-三氯嘧啶并[5,4-d]嘧啶(28)与2反应,然后用NH₃处理,也完成了34和36的明确合成。用1、6和28进行的亲核取代研究表明,这些化合物中卤素的反应活性顺序为8大于4大于6大于2。3和9的结构已根据¹H NMR数据确定,并通过单晶X射线衍射分析进一步证实。对本研究中合成的环外氨基核苷进行了体外抗几种RNA和DNA病毒以及在细胞培养中抗L1210、WI-L2和LoVo/L的活性测试。研究了这些化合物对从头核酸生物合成的影响。与ARPP(8)相比,化合物14(MRPP)在体内对L1210表现出增强的活性。